Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study

被引：0
|
作者：
Abelman, Rachel Occhiogrosso
Spring, Laura
Niemierko, Andrzej
Abraham, Elizabeth
McNeice, Mary
Goff, Jennifer
Valenti, Amanda
Wander, Seth Andrew
Isakoff, Steven J.
Moy, Beverly
Juric, Dejan
Vidula, Neelima
Waks, Adrienne Gropper
Parsons, Heather Anne
Ellisen, Leif W.
Tolaney, Sara M.
Bardia, Aditya
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] UCLA Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1102
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triplenegative breast cancer (TNBC): Translational investigation
    Bardia, Aditya
    Coates, James T.
    Spring, Laura
    Sun, Sheng
    Juric, Dejan
    Thimmiah, Nayana
    Niemierko, Andrzej
    Ryan, Phoebe
    Partridge, Ann
    Peppercorn, Jeffrey
    Parsons, Heather
    Wander, Seth
    Pierce, Kelsey
    Attaya, Victoria
    Fitzgerald, Donna
    Lormil, Brenda
    Shellock, Maria
    Nagayama, Aiko
    Bossuyt, Veerle
    Moy, Bev
    Tolaney, Sara
    Ellisen, Leif
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
  • [23] HEALTH UTILITIES ASSOCIATED WITH SACITUZUMAB GOVITECAN (SG) FOR TREATING UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
    Benedict, A.
    Rakonczai, P.
    Lovato, E.
    Proskorovsky, I
    Xiao, Y.
    Hodgson, M.
    McConkey, D.
    Gharaibeh, M.
    VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
  • [24] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2022, 8 (01)
  • [25] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [26] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [27] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [28] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [29] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Singh, Indrajeet
    Sathe, Abhishek G.
    Singh, Pratap
    Diderichsen, Paul M.
    Fauchet, Floris
    Maringwa, John
    Pierrillas, Philippe
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
12345